NORTH CHICAGO, Ill., May 5, 2026
AbbVie Inc. has presented extensive new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, highlighting long-term efficacy, safety, and durability of its key therapies SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) in Crohn’s disease and ulcerative colitis. The presentation of 18 scientific abstracts, including real-world evidence and clinical trial data, reinforces AbbVie’s leadership in inflammatory bowel disease (IBD) treatment innovation and underscores the growing importance of targeted immunotherapies in chronic inflammatory conditions.
Real-World Evidence Demonstrates Sustained Clinical Benefits
AbbVie’s data from the ASPIRE-CD study showed that patients with moderately to severely active Crohn’s disease treated with risankizumab experienced rapid and sustained symptom relief over 52 weeks, including improvements in abdominal pain, bowel urgency, and stool consistency. Notably, the use of corticosteroids decreased significantly from 34% at baseline to 7% at one year, while reliance on over-the-counter therapies also declined, indicating improved disease control and reduced treatment burden.
In addition, 77% of patients reported improved quality of life, including better daily functioning, work productivity, and overall wellbeing, demonstrating the broader impact of therapy beyond clinical endpoints. Patient satisfaction with treatment increased dramatically, reaching nearly 87% overall and 92% among those continuing therapy, highlighting strong treatment persistence and patient acceptance.
Comparative Data Highlights Rinvoq’s Clinical Advantage
Advertisement
Real-world analyses comparing treatment strategies revealed that patients who switched to upadacitinib (RINVOQ®) had 31% lower odds of hospitalization and 26% lower emergency department visits compared to those who escalated biologic dosing. These findings suggest that targeted JAK inhibition may offer superior disease control and healthcare resource optimization in patients with Crohn’s disease and ulcerative colitis.
Further clinical insights from Phase 3 trials demonstrated that upadacitinib delivered significant endoscopic improvements, even in patients with difficult-to-treat perianal fistulizing Crohn’s disease, including those with inadequate response to anti-TNF therapies. These results reinforce the role of advanced targeted therapies in addressing complex and refractory disease cases, positioning Rinvoq as a key treatment option in modern IBD management.
Advancing Treatment Standards in IBD Through Innovation
AbbVie’s comprehensive dataset reflects a broader shift toward precision medicine and long-term disease management in inflammatory bowel disease. By combining real-world evidence with controlled clinical trial data, the company demonstrates the durability of response, safety profile, and clinical effectiveness of its therapies across diverse patient populations.
The success of IL-23 inhibition (risankizumab) and JAK inhibition (upadacitinib) highlights the importance of targeted immune modulation in achieving sustained remission and improving patient outcomes. These therapies are designed to address the underlying inflammatory pathways driving IBD, offering a more effective and personalized approach compared to traditional treatments.
AbbVie’s continued investment in clinical research, data generation, and therapeutic innovation positions it at the forefront of the biopharmaceutical landscape, particularly in chronic immune-mediated diseases. The data presented at DDW 2026 not only strengthens confidence in existing therapies but also supports the evolution of treatment standards, emphasizing long-term remission, reduced healthcare utilization, and improved quality of life for patients.
Implications for Biopharma and Gastroenterology
The growing body of evidence supporting risankizumab and upadacitinib underscores the increasing role of biopharmaceutical innovation in managing chronic diseases. With IBD affecting millions globally, therapies that deliver sustained efficacy and safety are essential for reducing disease burden and healthcare costs.
AbbVie’s research highlights how integrated clinical and real-world data strategies can accelerate the adoption of effective therapies, providing clinicians with actionable insights and improving decision-making in complex cases. This approach aligns with the future of healthcare, where data-driven, patient-centric treatment models are becoming the standard.
Source: AbbVie press release
